Ductal Breast Carcinoma in Situ Clinical Trial
Official title:
Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women
This randomized phase III trial studies metformin hydrochloride to see how well it works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of metformin hydrochloride may prevent breast cancer.
I. Test for the presence or absence of cytological atypia (as measured by a Masood Cytology Index Score of 14-17) in unilateral or bilateral random periareolar fine needle aspiration (RPFNA) aspirates after 12 and 24 months (24 month is optional for placebo-only group for patients who remain on placebo arm and will not receive metformin [metformin hydrochloride]) for women receiving metformin versus placebo control. The presence of cytological atypia means any atypia in any RPFNA specimen. SECONDARY OBJECTIVES: I. Use the Masood Cytology Index Score to test for the presence of cytological atypia or disappearance of cytological atypia in RPFNA aspirates after 12 months for both arms, and 24 months (24 month is optional for placebo-only group for patients who remain on placebo arm and will not receive metformin, and mandatory for crossover patients) for women receiving metformin 850 mg orally (PO) twice daily (BID) (metformin group). II. Compare Masood Cytology Score values at 0 and 12 months in right and left breasts (if both breasts were aspirated) from the same individual in the metformin and placebo group. III. Test the reproducibility of reverse phase protein microarray (RPPM) in duplicate RPPM determinations from individual RPFNA specimens. IV. Correlate baseline RPPM values with presence of atypia (as measured by Masood Cytology Index Score) at month 12 and month 24 (month 24 optional for placebo-only group; for patients who remain on placebo arm and will not receive metformin) RPFNA. TERTIARY OBJECTIVES: I. Test whether metformin alters RPFNA or blood biomarkers associated with breast cancer risk. II. Test whether metformin alters markers associated with obesity and insulin resistance. III. Test other exploratory measures in RPFNA and serum including metformin levels and estrogen/progesterone. IV. Banking: As part of ongoing research for Alliance Cancer Control studies, banking residual blood and RPFNA products for future studies. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02314156 -
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
|
Phase 2 | |
Completed |
NCT01874184 -
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
|
N/A | |
Completed |
NCT01869764 -
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
|
Phase 2 | |
Completed |
NCT02587663 -
Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI
|
N/A | |
Active, not recruiting |
NCT04537312 -
Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM)
|
N/A | |
Active, not recruiting |
NCT01245712 -
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
|
Phase 2 | |
Recruiting |
NCT02993159 -
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
|
Phase 2 | |
Completed |
NCT01753908 -
Broccoli Sprout Extract in Treating Patients With Breast Cancer
|
Early Phase 1 | |
Terminated |
NCT02023008 -
Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy
|
N/A | |
Completed |
NCT01849250 -
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
|
Phase 2 | |
Terminated |
NCT01754519 -
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
|
Phase 2 | |
Completed |
NCT01819233 -
Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
|
N/A | |
Active, not recruiting |
NCT03077841 -
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02352883 -
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
|
N/A | |
Recruiting |
NCT03909282 -
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
|
N/A | |
Completed |
NCT01723943 -
Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients
|
N/A | |
Completed |
NCT00637481 -
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
|
Phase 1 | |
Completed |
NCT01975363 -
Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03391388 -
3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer
|
Phase 2 | |
Completed |
NCT02526498 -
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
|
Phase 2 |